Publicacions en col·laboració amb investigadors/es de University of Glasgow (2)

2022

  1. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

    The Lancet Diabetes and Endocrinology, Vol. 10, Núm. 1, pp. 35-45

2007

  1. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials

    Journal of the American Medical Association, Vol. 297, Núm. 12, pp. 1332-1343